All Paxlovid articles
-
NewsOptimal timing maximises Paxlovid benefits for treating COVID-19
Study suggests using the anti-COVID-19 treatment Paxlovid three to five days after symptoms emerge in patients and expanding global access to the drug may help reduce the severity and transmission of the SARS-CoV-2 virus.
-
NewsScientists uncover how coronavirus defends itself against our immune system
A research team identifies “protective switches” in the protein of the SARS-CoV-2 virus.
-
NewsOne in five patients experience rebound COVID after taking Paxlovid, new study finds
While Paxlovid remains a ‘life-saving drug,’ researchers found that patients experiencing virologic rebound after treatment may remain contagious.
-
NewsMolnupiravir dose of human effect size-equivalent blocks Covid transmission in ferrets
Two oral drugs provide equivalent therapeutic benefit in preventing severe COVID-19 in animal models, but only molnupiravir efficiently blocked SARS-CoV-2 transmission when administered at a human effect size-equivalent dose.
-
NewsResearchers use mass spectrometry to explore antimicrobial resistance
Researchers are using single-cell mass spectrometry to determine whether cells with persistent pathogens will also have less intracellular drug levels to potentially explain antimicrobial treatment failure.
-
NewsStudy finds evidence of resistance to COVID-19 drugs
Resistance to Paxlovid is already evident among viral SARS-CoV-2 variants currently circulating globally, indicating that this stand-alone drug known as a protease inhibitor could soon become less effective in treating COVID-19 infections, a new study suggests.
